CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective diligently but unsuccessfully to develop an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my past several shares. The first CytoDyn article of mine, “CytoDyn: What to be able to Do When It is Too Good to be able to Be True?”, set away the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such an extremely promotional image in the Uptick Newswire interview that I came away with an inadequate opinion of the business.

Irony of irony, my poor impression of the business has grown steadily, although the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this know-how and associated intellectual property coming from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) and the very first new drug application endorsement ($5 million), and also royalty payments of 5 percent of net sales after commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and numerous indications, it has this single therapies in addition to a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.

Its opening banner on the site of its (below) shows an active company with diverse interests albeit centered on leronlimab, several illness types, multiple delivering presentations and multiple publications.

Can it all be smoke and mirrors? That’s a question I have been asking myself with the very start of my interest in this particular organization. Judging by the multiples of a huge number of diverse commentary on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this particular question.

CytoDyn is a classic battleground, or even some might say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News